Head-to-head · WeighScore
Invyncible vs Mevo Health
The verdict
Invyncible takes it — 61/100 to 60.2/100, but only just.
Invyncible grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Invyncible is a Florida-based telehealth platform offering semaglutide and tirzepatide programs for weight management. Mevo Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Invyncible | Mevo Health |
|---|---|---|
| WeighScore | 61/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #303 | #327 |
| Semaglutide | $192/mo (0.5 mg dose, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $210/mo (compounded) | $259/mo (all doses, compounded) |
| Coverage | 40 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #303 · C
Strengths
- Corporate parent disclosed (Nationwide Telemedicine, LLC) — better than most competitors hiding behind trade names
- Physical corporate address published (St. Petersburg, FL)
- LegitScript verification seal displayed
- No long-term commitment required
- Offers both semaglutide and tirzepatide programs
Where it loses points
- Pricing not disclosed on the public site — fully gated behind signup
- Drug forms (compounded vs brand, injection vs oral) not disclosed
- 503A vs 503B designation not specified
- Pharmacy partner not named
- States served not listed publicly
Graded #327 · C
Strengths
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
Where it loses points
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.